Seelos Therapeutics, Inc. (SEEL)

Nasdaq Stock Exchange
USD
US81577F1093
19 April 1999  –  7 February 2023

Performance

Annualized Return
-32.2%
Sharpe Ratio
0.24
Maximum Drawdown
-100%

Metrics

Metric Seelos Therapeutics, Inc.
Initial Balance $10,000
Final Balance $1
Returns   [View more details]
Month-To-Date 5.9%
Year-To-Date 26.66%
3M -1.98%
6M -13.99%
Annual Return (3Y) -1.14%
Annual Return (5Y) -58.68%
Annual Return (All) -32.2%
Risk   [View more details]
Annual Volatility 118.76%
Max Drawdown -100%
Sharpe Ratio 0.24
Sortino Ratio 0.41
Adjusted Sortino (S/√2) 0.29

  • Initial balance: The amount of starting capital used to invest in the asset or portfolio. In this case, we're starting with a $10,000 investment on April 1999.
  • Final balance: The amount of capital we've accrued over time as of February 2023.
  • Annual return: Also known as annualized return, or CAGR (Compound Annual Growth Rate), measures how much an investment has increased on average each year, during a specific time period. The time period in this case is approximately 24 year(s). Even a small difference in return can have a big impact on the final balance over a long period of time.
  • Annual volatility: Basically indicates how much, in percentage points, the investment can deviate from its annual return, under most circumstances. An investment with an annual return of 5% and an annual volatility of 10% would indicate returns from approximately -5% to 15% most of the time. A lower volatility is usually preferred to ensure more steady returns over time.
  • Best year: The best performance attained over its lifetime in a given year.
  • Worst year: The worst performance undergone over its lifetime in a given year.
  • Max drawdown: The largest percentage drop from a peak to a trough of an asset or portfolio, before a new peak is attained. Maximum drawdown is an indicator of downside risk over a specified time period.
  • Sharpe Ratio: The Sharpe ratio measures the performance of an investment compared to a risk-free asset, after adjusting for its risk. A Sharpe Ratio above 1 is considered good.
  • Sortino Ratio: The Sortino Ratio is a variation of the Sharpe ratio that only penalizes the investment for negative volatility/outcomes, and not for positive volatility. A Sortino Ratio above 1 is considered good.
  • Adjusted Sortino Ratio: Sortino Ratio/√2. To allow for comparing the Sortino ratio to the Sharpe ratio, we multiply the risk measure of the Sortino ratio by the square root of 2 (which is the same as dividing the Sortino ratio by the square root of 2).
  • Ulcer Index: The Ulcer Index (UI) is a technical indicator that measures downside risk in terms of both the depth and duration of price declines.
  • Gain to Pain Ratio: The sum of all returns divided by the absolute value of the sum of all negative returns. In essence, the GPR shows the ratio of net returns to the losses incurred in getting those returns.

Annualized Returns

Annual Return 1y Annual Return 3y Annual Return 5y Annual Return 10y Annual Return 20y Annual Return
Seelos Therapeutics, Inc. -20.37% -1.14% -58.68% -50.66% -37.05% -32.2%

Annual Returns

Year Seelos Therapeutics, Inc.
1999 106.25%
2000 93.94%
2001 -57.5%
2002 -79.12%
2003 461.97%
2004 -62.41%
2005 -48.67%
2006 -12.99%
2007 111.94%
2008 -90.14%
2009 103.57%
2010 -18.83%
2011 48.7%
2012 -61.43%
2013 33.17%
2014 -62.26%
2015 -1%
2016 -86.87%
2017 41.54%
2018 -89.57%
2019 -76.74%
2020 17.91%
2021 3.16%
2022 -58.34%
2023 26.66%

Seelos Therapeutics, Inc. had 11 positive years and 14 negative years. That's a positive ratio of 44%.

Monthly Returns

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec YTD
1999 0% 0% 0% -15.7% -16.4% -29.1% 50% 0% 100% 25% 8.3% 1.6% 126.7%
2000 44.7% 130.4% 15.5% -18.1% -36.1% 14.3% -1.2% 57.7% 32.5% -15.3% -43.3% -15.2% 163.9%
2001 28.9% -36.4% -33.3% -3.8% 20.7% -15% 1.9% -24.1% -26% 41.3% -6.9% 4.6% -35.1%
2002 -16.2% 10.5% 50.8% -24% -19.7% -13.8% -24.8% 1.1% -3.2% -13% -64.4% 24.6% -41.9%
2003 77.5% 43.7% -32.6% 26.2% 2.6% 163.9% -0.5% -7.2% 4.2% 34.7% -17% -10.9% 239.4%
2004 2.8% -15.1% -19.5% -19.6% -21.3% 13% -6.5% -17.6% -3.2% -8.7% 0.7% 9.5% -69.7%
2005 -6.7% -5.7% -14.4% 21.2% -5.1% 0% 30% 4.7% -10.2% -20.8% -12.7% -30% -49.4%
2006 36.4% -1.9% -15.5% -8% -13.8% -11.6% 27.9% 1.3% -20.3% -22.2% 2% 34% 15.7%
2007 51.1% 28.4% -4.6% 9.7% 25% 7.1% -8.8% -2.4% 1.9% -13.3% -2.8% 2.2% 102.7%
2008 2.1% 5.5% -12.4% -17.9% 19.1% -0.8% 3.1% -85.8% -36.7% 0.7% -41.3% 97.2% -11.1%
2009 42.9% -56% 47.7% 15.5% 63.1% 93.9% -60.4% -1.3% -5.2% -25.5% 83% 18.7% 235.9%
2010 82.5% -12% 0.6% 4.1% -26.6% -60.2% 57.1% -40.6% -11.7% 2.3% 94.9% 0.6% 79%
2011 12.1% 37.8% -21.8% 33.9% -8% -7.2% -5% 5.3% -25.3% 20.4% 2.3% 17% 57.7%
2012 -1.4% -32.8% -17.5% -3.5% -3.4% 29.7% -2.6% -13.6% 13.6% -7.4% -27.2% -9.5% -79.3%
2013 32.7% 1.1% 0.4% 0.4% 2.2% -14.5% -5.5% -11.7% 6.6% -7.7% 2.5% 33.9% 48.2%
2014 -12.1% 0% -7.7% 3% 5.2% -3.4% -15.6% -0% -20.5% -2% -20.3% -15.3% -82.8%
2015 39% 58.3% -15% -14.4% 4.4% 2.4% -15.8% 18.1% -14.1% -9.6% -17.4% -9.2% 31.3%
2016 12.1% -5.4% -44.7% -8.2% -18.5% -8.2% -22.8% 13.7% -3.6% -40.6% -29.4% -8.5% -124.6%
2017 86.9% 19.3% -27.2% -46.4% -19.2% 23.7% 21.2% 19% 4.9% -2.3% -5.4% 16.5% 96%
2018 24.5% -59.8% -55.9% -33.6% 3.8% 39.3% -23.1% 10% -6% 9.3% -9.7% -37.3% -108.2%
2019 -21.9% -58.9% 81.6% -10.4% -20.6% -8.4% -20.1% -22.9% -32% -1.9% -4.5% 55.8% -56.5%
2020 -22.4% -15.7% -44.1% 44.8% 73.2% -17.9% 14.9% -21.5% 2.9% -21% 32.4% 61.2% 85.4%
2021 36.7% 37.5% 68% 22% -49.4% -14.3% -14.8% -2.2% 9.5% -10.4% -19.9% -5.8% 59.1%
2022 -30.1% -7% -21% -26% 4.6% 4.9% 23.5% 34.5% -8.8% -15.6% -5.8% -17.1% -43.5%
2023 19.6% 5.9% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 26.9%
Pos 70.8% 50% 30.4% 41.7% 45.8% 45.8% 37.5% 45.8% 37.5% 29.2% 33.3% 58.3% 56%
Avg 21.7% 3% -5.3% -2.9% -1.4% 7.8% 0.1% -3.6% -2.1% -4.3% -4.2% 9.1% 26.6%

Other Return Metrics

Metric Seelos Therapeutics, Inc.
Cumulative Return -99.99%
Enh Ann Return -5.6%
Best Year 461.97%
Worst Year -90.14%
Best Month 163.92%
Worst Month -85.82%
Best Day 159.8%
Worst Day -81.62%
Win Ratio (Yearly) 44%
Win Ratio (Quarterly) 39.58%
Win Ratio (Monthly) 43.9%
Win Ratio (Daily) 45%

Annual Volatility

Annual Volatility 1y Annual Volatility 3y Annual Volatility 5y Annual Volatility 10y Annual Volatility 20y Annual Volatility
Seelos Therapeutics, Inc. 95.63% 108.1% 123.09% 110.22% 115.8% 118.76%

Sharpe Ratio

Sharpe Ratio 1y Sharpe Ratio 3y Sharpe Ratio 5y Sharpe Ratio 10y Sharpe Ratio 20y Sharpe Ratio
Seelos Therapeutics, Inc. 0.23 0.51 -0.11 -0.11 0.15 0.24

3-Year Rolling Sharpe Ratio

The rolling Sharpe Ratio gives a clue about the continued consistency or stability of the risk-adjusted returns.

Drawdown Periods

Simply said, a drawdown is the "pain" period experienced by an investor between a peak (new highs) and subsequent valley (a low point before moving higher). In the table below are the fifth largest drawdowns encountered for the portfolio/asset in question.

Seelos Therapeutics, Inc.

start valley end Drawdown days
2000-03-06 2020-04-02 - -100% 8373
1999-04-27 1999-06-28 1999-09-09 -53.15% 135
1999-09-13 1999-09-15 1999-09-29 -28.88% 16
2000-02-22 2000-02-23 2000-03-02 -27.47% 9
1999-10-22 1999-11-05 1999-11-23 -21.44% 32

The Seelos Therapeutics, Inc. took approximately 57 months on average to recover from a major drawdown. The longest drawdown lasted 279 months.

Underwater plot

The underwater plot shows you the drawdown periods on a chart. Whereas the performance chart usually gives you a positive viewpoint, the underwater plot gives you a pessimistic viewpoint. It helps you to visualize downtrends that occurred and how long it took for the portfolio's value to rebound to hit a new high after suffering a loss.

Other Risk Metrics

Metric Seelos Therapeutics, Inc.
Sharpe Ratio 0.24
Sortino Ratio 0.41
Adjusted Sortino (S/√2) 0.29
Calmar Ratio -0.32
Omega Ratio -0.32
Gain to Pain Ratio 0.05
Winckel Ratio 56
Ulcer Index 0.93
Kelly Criterion 2.29%
Skew 3.55
Kurtosis 62.27
End of: